atezolizumab,nivolumab,durvalumab,pembrolizumab
roche,astrazeneca,merck,bms
['lung', 'imfinzi', 'keytruda', 'opdivo', 'tecentriq', 'breast', 'bladder']
just released at #asco2022! #determaio posters presented by add to the growing body of evidence showing that the test identifies patients who respond to icis including keytruda , opdivo , tecentriq and imfinzi in lung, bladder, kidney, triple-negative breast
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum